1. Volatile organic compounds in breath as markers for irritable bowel syndrome
- Author
-
Agnieszka Baranska, Jackie A M Dekens, Ad A.M. Masclee, Cisca Wijmenga, Alexandra Zhernakova, Jan W. Dallinga, Ettje F. Tigchelaar, Agnieszka Smolinska, F. J. van Schooten, Daisy Jonkers, Zlatan Mujagic, Thomas Ludwig, Promovendi NTM, RS: NUTRIM - R4 - Gene-environment interaction, MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), Interne Geneeskunde, Farmacologie en Toxicologie, RS: NUTRIM - R2 - Gut-liver homeostasis, MUMC+: MA Maag Darm Lever (9), Translational Immunology Groningen (TRIGR), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), and Department of Health and Life Sciences
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Gastrointestinal Diseases ,Population ,BIOMARKERS ,General Population Cohort ,GASTROINTESTINAL DISORDERS ,Disease ,EXHALED AIR ,DIAGNOSIS ,Gastroenterology ,DISEASE ,VALIDATION ,Irritable Bowel Syndrome ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,LUNG-CANCER ,Internal medicine ,IBS ,Medicine ,Humans ,Metabolomics ,Pharmacology (medical) ,Young adult ,education ,Irritable bowel syndrome ,education.field_of_study ,Volatile Organic Compounds ,Hepatology ,business.industry ,Confounding ,Case-control study ,Middle Aged ,medicine.disease ,030104 developmental biology ,Breath gas analysis ,Breath Tests ,Case-Control Studies ,030211 gastroenterology & hepatology ,Female ,business - Abstract
BackgroundThe diagnosis of irritable bowel syndrome (IBS) is challenging because of its heterogeneity and multifactorial pathophysiology. No reliable biomarkers of IBS have been identified so far.AimsIn a case-control study, using a novel application of breath analysis to distinguish IBS patients from healthy controls based on the analysis of volatile organic compounds (VOCs). Subsequently, the diagnostic VOC-biomarker set was correlated with self-reported gastrointestinal (GI) symptoms of subjects of the Maastricht IBS clinical cohort and of a general population cohort, LifeLines DEEP.MethodsBreath samples were collected from 170 IBS patients and 153 healthy controls in the clinical cohort and from 1307 participants in general population cohort. Multivariate statistics were used to identify the most discriminatory set of VOCs in the clinical cohort, and to find associations between VOCs and GI symptoms in both cohorts.ResultsA set of 16 VOCs correctly predicted 89.4% of the IBS patients and 73.3% of the healthy controls (AUC = 0.83). The VOC-biomarker set correlated moderately with a set of GI symptoms in the clinical (r = 0.55, P = 0.0003) and general population cohorts (r = 0.54, P = 0.0004). A Kruskal-Wallis test showed no influence from possible confounding factors in distinguishing IBS patients from healthy controls.ConclusionsA set of 16 breath-based biomarkers that distinguishes IBS patients from healthy controls was identified. The VOC-biomarker set correlated significantly with GI symptoms in two independent cohorts. We demonstrate the potential use of breath analysis in the diagnosis and monitoring of IBS, and a possible application of VOC analyses in a general population cohort.
- Published
- 2016